PMID- 33603734
OWN - NLM
STAT- MEDLINE
DCOM- 20210614
LR  - 20210614
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 11
DP  - 2020
TI  - Pleiotropic Effects of Metformin on the Antitumor Efficiency of Immune Checkpoint 
      Inhibitors.
PG  - 586760
LID - 10.3389/fimmu.2020.586760 [doi]
LID - 586760
AB  - Cancer is an important threat to public health because of its high morbidity and 
      mortality. In recent decades, immune checkpoint inhibitors (ICIs) have ushered a 
      new therapeutic era in clinical oncology. The rapid development of immune 
      checkpoint therapy is due to its inspiring clinical efficacy in a group of cancer 
      types. Metformin, an effective agent for the management of type 2 diabetes 
      mellitus (T2DM), has shown beneficial effects on cancer prevention and cancer 
      treatment. Emerging studies have suggested that metformin in combination with ICI 
      treatment could improve the anticancer effects of ICIs. Hence, we conducted a 
      review to summarize the effects of metformin on ICI therapy. We also review the 
      pleiotropic mechanisms of metformin combined with ICIs in cancer therapy, 
      including its direct and indirect effects on the host immune system.
CI  - Copyright (c) 2021 Liu, Wang, Luo, Liu and Luo.
FAU - Liu, Wenhui
AU  - Liu W
AD  - Department of Pharmacy, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - Institute of Clinical Pharmacy, Central South University, Changsha, China.
FAU - Wang, Ying
AU  - Wang Y
AD  - Department of Pharmacy, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - Institute of Clinical Pharmacy, Central South University, Changsha, China.
FAU - Luo, Jianquan
AU  - Luo J
AD  - Department of Pharmacy, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - Institute of Clinical Pharmacy, Central South University, Changsha, China.
FAU - Liu, Mouze
AU  - Liu M
AD  - Department of Pharmacy, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - Institute of Clinical Pharmacy, Central South University, Changsha, China.
FAU - Luo, Zhiying
AU  - Luo Z
AD  - Department of Pharmacy, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - Institute of Clinical Pharmacy, Central South University, Changsha, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210202
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Immune Checkpoint Inhibitors/*pharmacology
MH  - Metformin/*pharmacology
MH  - Neoplasms/*drug therapy
PMC - PMC7884468
OTO - NOTNLM
OT  - PD-1
OT  - PD-L1
OT  - gut microbiome
OT  - immune check inhibitors
OT  - metformin
OT  - pleiotropic
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/02/20 06:00
MHDA- 2021/06/16 06:00
PMCR- 2020/01/01
CRDT- 2021/02/19 06:05
PHST- 2020/07/24 00:00 [received]
PHST- 2020/12/16 00:00 [accepted]
PHST- 2021/02/19 06:05 [entrez]
PHST- 2021/02/20 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2020.586760 [doi]
PST - epublish
SO  - Front Immunol. 2021 Feb 2;11:586760. doi: 10.3389/fimmu.2020.586760. eCollection 
      2020.